AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).

Upadacitinib induction therapy provided steroid-free clinical remission in over half of the patients with refractory Crohn's disease. Additionally, two thirds of the patients experienced a ...

AbbVie announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (Rinvoq; 15 mg, once ...

Rinvoq (upadacitinib) is a prescription drug used to treat certain autoimmune conditions. This drug can interact with some medications, vaccines, and supplements. For example, Rinvoq can interact ...

(RTTNews) - AbbVie (ABBV) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib ...